Ephrin type-A receptor 2 (EphA2) CAR T cells have been developed to target the EphA2+ U373 glioma xenograft mouse model and the results indicated that CARs with a short spacer had significantly greater antitumor activity, which could be augmented by transgenic expression of cytokines to counteract the immunosuppressive TME [82]. Here, EPHA2 is linked to glioma.